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Abstract
Antibodies to double-stranded DNA are important in the
pathogenesis of nephritis, a major clinical manifestation in lupus
patients. Since earlier diagnosis of renal involvement may lead to
better outcomes, identification of the nephritogenic specificity of
lupus-associated autoantibodies is important in understanding the
disease, while monitoring their titer clinically may serve as an
improved biomarker. Based upon work in animal models and cross-
sectional human studies, kidney α-actinin was thought to be a
plausible cross-reactive target for pathogenic lupus antibodies.
Manson and colleagues longitudinally evaluated anti-nucleosome,
anti-DNA, and anti-α-actinin antibodies in 16 lupus patients with
new-onset nephritis. While anti-nucleosome and anti-DNA antibody
levels were significantly associated and correlated with measures
of kidney disease, these were not found to be significant with anti-
α-actinin antibodies. While in lupus patients the diagnostic use of
serum anti-α-actinin antibodies, alone or with other novel
biomarkers, is still under investigation, such studies are vital in
improving our monitoring of systemic lupus erythematosus patients
and in developing new treatment paradigms that meet the
continuing clinical challenge of lupus nephritis.
In the previous issue of Arthritis Research & Therapy,
Manson and colleagues [1] report the results of their valuable
study in which they longitudinally followed systemic lupus
erythematosus (SLE) patients with new onset of lupus
nephritis (LN) while measuring the titers of autoantibodies
against  α-actinin, nucleosomes, and double-stranded DNA
(dsDNA). Based on the known link of these specificities to
nephritis, the authors set out to measure the correlation
between these three autoantibodies and determine how well
each reflected the renal outcome.
Indeed, LN remains a major challenge for clinicians treating
lupus patients. Despite the use of potent immuno-
suppressives, many patients fail to enter into remission, while
drug regimens used today can be associated with serious
side effects or poor patient tolerance or both [2]. Assuming
that earlier diagnosis of LN is associated with better
outcomes, investigators are undertaking major efforts to
identify serologic markers to assist in diagnosis and follow-up
and thereby improve prognosis. Since autoantibodies are
crucial in LN pathogenesis [3], identifying the specificities of
such nephritogenic antibodies is an important objective.
While anti-dsDNA autoantibodies have been closely linked to
the pathogenesis of LN, the mechanisms by which they
induce nephritis remain unclear [3,4]. Many authorities
believe that the pathogenicity of anti-DNA antibodies is
mediated by ‘indirect’ or ‘direct’ cross-reactivity. In the
indirect model, the binding of anti-DNA antibodies to renal
antigens is mediated by a bridge of nuclear antigens,
specifically nucleosomes [5]. In contrast, the direct model
implies that the binding of anti-nuclear antibodies to DNA/
nucleosomes is irrelevant to their nephritogenicity. Rather, it
is direct binding to cross-reactive kidney antigens which
leads to renal immunoglobulin (Ig) deposition. Strong support
for the central role of non-nuclear antigen-binding auto-
antibodies in the pathogenesis of LN can be found in the
seminal observation that less than 10% of the total IgG eluted
from kidneys of LN patients was accounted for by antibodies
binding to dsDNA, C1q, Sm, SSA (Sjögren syndrome
antigen A), SSB, histone, and chromatin [6]. Additional
impetus to search for kidney antigens bound by non-dsDNA-
specific antibodies is found in a study by Waters and
colleagues [7], which demonstrated that abrogation of
tolerance to nuclear components may not be required for the
development of LN in a lupus animal model.
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In our studies to discover the renal target antigen for
pathogenic autoantibodies, we had identified α-actinin in
mesangial cells as a plausible candidate in murine lupus.
Furthermore, high titers of anti-α-actinin antibodies were
present in the serum and kidney eluates of LN mice [8]. Our
results confirmed and extended those reported by
Mostoslavsky and colleagues [9], who had previously found
that the renal pathogenicity of murine lupus antibodies was
dependent on direct α-actinin binding. Subsequently, we
found that there are ACTN polymorphisms in MRL-lpr lupus
mice and that enhanced expression of α-actinin may
determine the extent of antibody deposition [10]. These
observations, together with the demonstration that α-actinin
immunization generates nephritogenic autoantibodies [11],
strongly suggested a possible role of α-actinin as an
important kidney target for pathogenic antibodies and
encouraged studies in human disease.
Human studies have shown that anti-dsDNA antibodies from
lupus patients with active nephritis displayed an increased
binding to α-actinin as compared with patients with no
nephritis [12] and that pathogenic human anti-dsDNA
antibodies bound strongly to α-actinin [12,13]. Moreover, an
increase in serum anti-α-actinin antibodies in lupus patients
was associated with a 2.5-fold increase in the prevalence of
LN [14]. Finally, levels of anti-α-actinin antibodies correlated
with those of anti-DNA antibodies and were significantly
higher in patients with renal flares [5]. While these results
were quite telling, studies looking at serial determinations of
anti-α-actinin antibodies over time were necessary for proving
more conclusively a pathogenic as well as a diagnostic role
for these autoantibodies in human lupus.
In their prospective study, Manson and colleagues [1] directly
compared the titers of anti-α-actinin, high-avidity anti-dsDNA,
and anti-nucleosome antibodies in 16 patients with new
onset of biopsy-proven LN followed for up to 2 years. In
addition, at each follow-up visit, urine protein/creatinine ratio,
serum albumin, a renal disease composite score, and renal
remission status were determined. Only 2 of 16 patients
showed high anti-α-actinin antibody titers at baseline.
Whereas a significant association was found between anti-
nucleosome and anti-dsDNA antibody levels, with each
showing a positive correlation with urine protein/creatinine
ratio and a negative correlation with serum albumin, these
were not found to be significant with anti-α-actinin antibodies.
How can the discrepancies between these disappointing
results and the previous studies be explained? No doubt, a
longitudinal design is important, although the number of
patients who were studied was relatively low, especially
considering that only 7 of the 16 patients had pure
proliferative disease (in which the association with patho-
genic antibodies is the strongest). The low frequency of α-
actinin antibodies in this cohort also has to be considered
since in previous studies about 20% of SLE patients had
increased anti-α-actinin antibodies [5,14]. Moreover, the lack
of a difference in α-actinin antibody titers between patients
with LN and controls is in contrast to what was reported
previously in two independent cohorts [5,14]. Variations
between the different studies could also be ascribed to the
drug regimens: all of the patients followed by Manson and
colleagues [1] were being treated, and anti-α-actinin antibody
titers may decrease with therapy. Finally, perhaps anti-dsDNA
antibodies not measured by the assay used in this particular
study would show a better correlation with anti-α-actinin
antibodies.
Although intensive efforts are being invested into developing
a more targeted lupus therapy that would be, if not more
effective, at least better tolerated and with fewer side effects,
several recent trials examining promising new therapies were
not able to demonstrate any major benefit over existing
modalities. Therefore, the challenge remains to use our
existing treatments more effectively by developing ways to
anticipate renal flares and their outcome and to profile kidney
pathology without resorting to repeat renal biopsy [2]. While
the results reported by Manson and colleagues [1] do not
provide support for the widespread application of serial
monitoring of anti-α-actinin antibodies in lupus patients at the
present time, additional studies to confirm these results in a
larger number of patients are surely indicated.
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